Prior to that, Tom held an Operations Supervisor role at Bracebridge Capital, LLC and operations positions at Harvard Management Company and State Street Corporation. Alyssas primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. PETER KOLCHINSKY, PhD Managing Partner RAJEEV SHAH Managing Partner ANDREW LEVIN, MD/PhD Partner and Managing Director JOSH RESNICK, MD Senior Managing Director PETER BALOGH Analyst GUNES BOZKURT, PhD Analyst TESS CAMERON Principal NATE DAVIS Analyst DEREK DiROCCO, PhD Partner CRISTINA GHENOIU, PhD Principal MICHAEL GILLESPIE, MD Analyst Ed Monaghan is an EIR at RA Capital. David holds a BS in Economics with a minor in Business Administration from University of Colorado Boulder. Max DeNies is a Senior Associate with the TechAtlas division of RA Capital Management. Drew has a BS in Chemical Engineering from University of Virginia and a PhD in Chemical Engineering from Massachusetts Institute of Technology. She works with RAs newcos to develop optimal pitch decks and public messaging, authors articles, and runs the firms internal and external business courses. Prior to this role, Cristina mapped a number of competitive landscapes, including respiratory, allergic, and infectious disease conditions. Merediths primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. Senior Research Assistant, Venture Analytics. Prior to this, he was a Postdoctoral Fellow at NYU Medical School in the laboratory of Dr. Danny Reinberg, exploring the functional downstream consequences of changes to the histone posttranslational modification landscape on processes that require access to DNA, including the regulation of gene expression. Peter Kolchinsky, PhD '01, is a founder, Portfolio Manager, and Managing Director at RA Capital Management, LLC, a multi-stage investment manager dedicated to evidence-based investing in healthcare and life sciences. in Anthropology and Natural Sciences and an M.S. Robert has led multiple DARPA, IARPA, and NIH advanced technology development programs. In his most recent role as Entrepreneur In Residence and Head of Computation at RA Ventures (RAVen), Soumya Ray supported the creation of two RAVen-incubated newcos. Meredith holds a BS in Biology: Pre-Med from the University of North Carolina at Charlotte. Christy is a Senior Associate with the TechAtlas division of RA Capital Management. In his most recent role as Entrepreneur In Residence at RA Ventures (RAVen), Michael worked closely with the Venture Team to evaluate drug discovery platforms and initiate novel therapeutic programs. Dan Marks is a Principal on the Venture Team at RA Capital Management. She holds a BS in Corporate Finance & Accounting and an MBA from Salem State University. Most recently, Joe led the administration and support of all Apple products at Curriculum Associates as an IT Systems Engineer. Peter Kolchinsky An excellent example of when knowledge meets power, former Harvard virology doctoral recipient Kolchinsky has put his brainpower to work behind RA Capital Management, with astonishing results in biotech specialization. Currently, Dr. Kolchinsky occupies the position of Chairman & Chief Executive Officer of Research Alliance Corp. II (which he founded in 2020) and Managing Partner at RA Capital Management LP (which he founded in 2004), Managing Partner at RA Capital Management LP (Private Equity) (which he founded) (a subsidiary of RA Capital Management LP). Sonia Kartha is an Associate with the TechAtlas division of RA Capital Management. In these commercial roles, he initiated innovative discovery deal structures with venture companies, research foundations, and large integrated deals with pharmaceutical companies. In his doctoral research, he investigated clinically translatable treatments for musculoskeletal tissue repair using injectable hydrogels. Jessica holds a BA in Linguistics from Brigham Young University and a PhD in auditory neuroscience from the Division of Medical Sciences at Harvard University. Laura Tadvalkar is a Managing Director on the Venture Team at RA Capital Management. Assistant General Counsel (RA Capital), RAVen Counsel. Priscilla has a B.S. Prior to his time at Merck, Michael held discovery leadership roles at Immunext and Tolerx. Prior to joining Achillion, Milind was Group Leader at Bristol-Myers Squibb for all early stage discovery programs in infectious diseases and neuroscience. Ding Sun is a Senior Software Engineer at RA Capital Management. Not so long ago, his mother and father were not rich. Brendan is a Tax Director at RA Capital Management. Michael has also previously held the position of Vice President and General Manager at Thomson Medstat (now part of IBM Watson Health), as well as held management roles at Immusol, a San Diego-based biotechnology company, HealthAllies, an organization created to provide discretionary medical benefits to the cash-pay market, and Da Vita, a national provider of dialysis services. Scott brings to RAVen 20 years of experience working with clients and portfolio companies to complete transactions including multiple IPOs and acquisitions of portfolio companies. At Ra Pharma, Alonso held various leadership roles where he initiated and led the scientific efforts for the company in multiple preclinical and clinical programs; working in a wide set of therapeutic areas and using different molecular modalities. Prior to RA, Henry gained experience as an Investment Banking Analyst at SVB Leerink. Jaime is an Executive Assistant at RA Ventures (RAVen). Drews primary responsibility is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. Prior to joining RA Capital, Emilie was a Vice President of Investor Relations at THL Credit. Dr. Kolchinsky is a founding Partner and Portfolio Manager at RA Capital. He has held multiple senior level clinical development positions including Chief Medical Officer at Asceneuron SA and Neurodegeneration Therapeutic Area Head at Novartis. He is a member of the Advisory Boards of the Applied Biotechnology Laboratory at the Francis Crick Institute, the Center for Surgery,Innovation & Bioengineering at the Massachusetts General Hospital/Harvard MedicalSchool; the Chemical& Biomolecular Engineering Department of the University of Illinois and the Biomedical Engineering Departmentof Rutgers University. Josh is a Senior Research Assistant at RA Capital Management. Previously, Michael worked closely with the Investment Team, to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Sophie is Chief Medical Officer at Enara Bio, a company focused on novel targets for cancer immune therapy drug discovery. Peter Kolchinsky Founder and CEO RA Capital Management. Derek holds a BA in Biology from Holy Cross College and a PhD in Pharmacology from the University of Washington. in Immunology from National Taiwan University College of Medicine, and a PhD in Biomedical Science from The Ohio State University. Mariagrace previously worked as an Executive Assistant at MPM Capital. Prior to Avilar, Mr. Grau was CEO at Sojournix, President at Heptares Therapeutics (acquired 2015), CEO at Cortria (acquired 2010), and COO at CombinatoRx (IPO 2005). Sarah teaches a course at Harvard Law School on venture capital fund formation. Patrick was instrumental to building Constellations discovery platform, establishing a portfolio of competitive clinical candidates and drove the maturation of the companys development efforts, leading to one PhIII and two PhII assets and three additional clinical candidates. TJ is a Senior Fund Accountant at RA Capital Management. Joel is currently a Venture Partner at RA Ventures focusing on new company creation. Matt has a BA in Biology with minors in Mathematics and Physics from Ithaca College, a Master of Science in Bioinformatics from Northeastern University, and a PhD in Molecular Biology with a specialization in quantitative biology from Brandeis University. Amber is Special Projects Operations Manager/Chief of Staff at RA Capital Management. As President, U.S. Pharmaceuticals at Bayer, he directed a multi-billion-dollar portfolio of products across multiple therapeutic areas (cardiovascular disease, hematology, neurology, oncology, and women's health). Emily Greenis a Visual Identity Designer at RA Capital Management. Prior to Mintz, Kate held a Paralegal role at Loughran & Corbett, Attorneys, Inc. Kate holds a Bachelor's Degree in Political Science from Bridgewater State University and is a certified Paralegal in Massachusetts. Zach Scheiner is a Principal on the Investment Team at RA Capital Management. While at Johns Hopkins, she spent two years as a Research Intern and Teaching Assistant in the Department of Biology and the Department of Chemistry. Laura previously worked at WinterWyman where she served as a Senior Associate. Her doctoral research focused on bacteriophage-mediated regulation of bacterial transcription. Peter Kolchinsky @PeterKolchinsky 2h So competition among vaccine innovators required collaboration to expand production and rewards were high enough to hire all capable people in the world to work on this. As Executive Director of Business Development at Celgene, Emily was responsible for all aspects of deal evaluation, negotiation, and execution for licensing deals, mergers and acquisitions, and collaborations, with a focus on immune-inflammatory and neurodegenerative diseases. Mark Boshar is a Venture Partner at RA Ventures (RAVen), focusing on new company creation. Prior to founding The Branta Group LLC in 2003, he was a co-founder and Chief Business Officer of Orchid GeneShield, a subsidiary of Orchid BioSciences (Nasdaq: ORCH), which was formed after he acquired a healthcare informatics company and merged it with Orchids pharmacogenetics business to create innovative personalized consumer healthcare products in partnership with leading healthcare companies. Joe DeMaio is IT Operations Associate at RA Capital Management. As political refugees, the family was placed in Milwaukee, then Pittsburgh. He authored the e-book "The Entrepreneur's Guide to a Biotech Startup". Jeff Breay is a Head Trader at RA Capital Management. What is Peter Kolchinsky Net Worth? 1 reply 0 retweets 13 likes He holds a BA in Environmental Engineering from Dartmouth College (1998), an MA in International Finance and Energy Policy from John Hopkins University (2008), an MS in Materials Science from Columbia University (2012), and a Masters of Strategic Studies from the Army War College (2020). Her primary responsibilities are to assist with all finance operations related to the Firm. Ben previously worked as a Research Assistant in a Neuroinflammation lab at Brigham and Womens Hospital/Harvard Medical School, and was an Internet Application Developer at the Gallup Organization. He earned his MS in Bioinformatics from Boston University. Before transitioning to industry, Cosmas was a faculty member at Harvard Medical School/Massachusetts General Hospital (MGH), where he had an active gastroenterology clinical practice and ran a lab whose research centered on fundamental aspects of RNA and epigenetics. He was previously a marketing manager at Brighton House Associates, assisting with fundraising campaigns for a diverse group of investment managers, including private equity, venture capital, real estate, and hedge funds. Candice has a BS in Mass Communications from Emerson College. He holds BA and MA degrees in immunology from the University of Cambridge, an MD from University College London, and an MAS in clinical research from UCSF. "Too old," said a man in his 70s. Zach works on both public and private investments and serves as a Board Director for Adagio Medical, Exo Imaging, LENZ Therapeutics, Nkarta Therapeutics, and Sydnexis. From 2016-2017, Scott served as President of Sojournix, Inc., an asset-focused biopharmaceutical company that he co-founded and served as Board member until 2021. He has over 20 academic publications, inventorship on numerous patents, and serves as reviewer for multiple journals and NIH grants committee. Lorena Chen is a Fund Controller at RA Capital Management. At BPS, Joe provided technical support for teachers and staff and was Jamf certified to manage Apple products. Prior to joining RA Capital, Jeff worked for over 10 years as an institutional equity sales trader, primarily at KCG Holdings, Inc., where he managed the Boston office. Kate previously served as Health Law Assistant at Mintz. Hearing the stories of how patients couldn't afford the . Prior to MPM, she worked as an Executive Assistant at Charles River Ventures. Chris Morrison is an Editor at RA Capital Management. Prior to management consulting, Mr. Grau was Director of Marketing & Business Development at a clinical information technology startup. Prior to Merck, he was a Partner with the Partners Innovation Fund, the corporate venture arm of Mass General Brigham hospital (formerly Partners HealthCare), where he invested in Seed/Series A therapeutics-focused companies. Cony D'Cruz is a Venture Partner at RA Ventures. This website is for informational purposes only and does not constitute an offer to provide investment advisory or other services by RA Capital Management, L.P. (RA Capital). In his Venture role, Mario is focusing on early-stage investment and company creation. Raj holds a BA from Cornell University, where he majored in Chemistry. All information is subject to change and may quickly become unreliable for various reasons, including changes in market conditions or economic circumstances. Joshs primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Americas +1 212 318 2000. He holds a BA in History from University of Massachusetts, Amherst and a Master's of Urban Affairs from Boston University. He completed his residency in internal medicine at Yale-New Haven Hospital and completed his clinical gastroenterology fellowship at Massachusetts General Hospital / Harvard Medical School as well post-doctoral training with Frederick Alt, an HHMI investigator, in molecular immunology. Sadik holds a bachelor of science degree in Cell and Molecular Biology from Tulane University, and earned his PhD in Microbiology and Immunology from Louisiana State University. Tylers primary responsibility at RA Capital isdesigning and maintaining the RA Capital website and assisting in the creation and design of interactive platforms at RA Capital and it's portfolio companies founded through the firm's incubator, RA Ventures. Katherine Terranova is an Associate within the TechAtlas division of RA Capital Management. Prithviraj comes to RA from CVS Health, where he was Director of HealthHUB Product Technology Strategy and Enablement. He previously worked as a corporate attorney at Foley Hoag LLP and Cooley LLP. As the first and founding member of Kymeras scientific team, Jesse was responsible for building the companys industry-leading targeted protein degradation platform and pipeline, and he helped secure the companys Series A and B financings as well as a partnership with Vertex. Drinking, Drugs & Smoking Not present. Shannon's primary responsibilities are to manage the front desk and office facilities. Nadim has 11+ years experience in commercializing drug discovery across diverse indications and modalities. Within the last 20 years alone, PJ Hogan had a go with 2003's Peter Pan (a major, almost $100m-losing flop), Joe Wright tried again in 2015 with the more radical Pan (another massive failure . He holds a Bachelors degree in Electronics and Communications from Anna University, and a Masters degree in Computer Science from Northeastern University. Matthew holds a BS in Environmental Health Science from the University of Georgia and both a PhD in Biomedical Science and an MBA with a concentration in Finance from the University of Connecticut. Previously, Shan Shan covered Orphan Heme, Orphan GOF, Vaccines, and various Gene Therapies as a Senior Associate. Prior to Flagship, Emily held roles as Associate Director, Head of Global Talent Acquisition and Associate Director, Recruiting Operations & Analytics at bluebird bio. Peter's age is in line with some of the older Vanderpump Rules cast members, like Jax, Tom Sandoval, and Tom Schwartz. Previously, Derek covered solid tumor oncology landscapes. Garrett received a BS with honors from the California Institute of Technology while publishing his first paper with Dr. Paul H. Patterson, holds a PhD in Immunology from Stanford University, where he studied hematopoietic stem and progenitor cells with Dr. Irving L. Weissman, and completed his post-doctoral training at Childrens Hospital Boston/Harvard Medical School studying ES/iPSC specification to the hematopoietic fate with Dr. George Q. Daley. Elena's primary responsibility at RA Capital is to create competitive landscapes of biotechnology and planetary health. Finally, they made it to the Boston. Merediths previous experience includes Medical Education Researcher and Medical Scribe positions at BMC Global Inc. and Longwood Pediatrics, respectively. Peter Pan has long been a character that audiences have held up a critical lens to, as the premise of an eternal boy who recruits isolated children naturally brings up some questions the more a person thinks about it. Prior to RAVen, Natalie served as an EA for three years at Massachusetts Technology Collaborative (MassTech), a Boston agency supporting business formation and growth in the state's technology sector. She also held research roles at MIT, Children's Hospital, Harvard, and Brigham and Women's Hospital. Michael is chair of the Board of Managers of the Harvard Pilgrim Health Care Institute. Josh holds a BA in Chemistry from Williams College, an MD from the University of Pennsylvania School of Medicine, and an MBA from the Wharton School of Business. Emily Minkow is a Venture Partner at RA Ventures. Prior to joining the team at Enara Sophie was a medical oncologist at Guys and St Thomas NHS Foundation Trust in London, UK (GSTT). Prior to MP, she was a Consultant at Clarion Healthcare. and Novus Biologicals. Patrick joined TRIANA Biomedicines in December of 2021 as President & CEO and Board member after a successful career at Constellation Pharmaceuticals where he served as the companys CSO. He holds a BA from Cornell University and a PhD in Virology from Harvard University. His most recent role at Biogen was as Senior Vice President, U.S. Commercial, where he was the general manager of the MS, hemophilia, and SMA franchises. Vanderpump Rules' Peter Madrigal's Age. Cristina holds a BA in Molecular Biology with a minor in Business from Washington University in St. Louis, and a PhD in Microbiology and Molecular Genetics from Harvard University. Prior to RA, Christy was a Senior Scientist in Oncology Target Discovery at Pfizer. Scott received his Bachelor of Science from the University of Illinois and his Ph.D. from the Massachusetts Institute of Technology. Previously, Gunes worked closely with the Investment Team, as a Senior Associate within RAs TechAtlas division. Kevin's primary responsibilities is to research early-stage projects in collaboration with RAVen team members, Venture Partners, and Entrepreneurs-in-Residence. Peter has a BS in Biology with minors in both Chemistry and Spanish for the Medical Professions from the University of North Carolina at Chapel Hill. He was also a Board Member of the Fannie & John Hertz Foundation and served as a judge for the Lemelson-MIT StudentPrize for Inventorship. He was also responsible for initiating the transition of the autoimmunity strategy from one based on systemic immunosuppression to a targeted immunomodulation approach. Peter conducts due diligence on biotechnology companies at RA Capital, and advises RA's portfolio companies on many aspects of program and pipeline strategy. He is a respected biotech leader with over twenty years of biopharma experience across global organizations. He had to juggle the demands of raising a family while also trying to pay for his children's education. Prior to Biogen, Mike worked at Bain & Company as a consultant specializing in healthcare. Sophie is a Fellow of the Royal College of Physicians, London, UK. He has more than 15 years of experience in investing, company formation, and company leadership across all stages of drug development, from discovery through commercialization. Earlier in his career, he was Head of Early Analytical Development for Novartis Cell and Gene Therapies Unit and worked on research teams at the National Cancer Institute with Dr. Steven Rosenberg, the University of Pennsylvania Gene Therapy Program with Dr. Jim Wilson, and Johnson and Johnsons Immunology Discovery group. Fuads primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Parents Need to Know. Peter Kolchinsky was born in the United States of America. Previously in his career, he served as Associate General Counsel at Millennium Pharmaceuticals (now Takeda Oncology) where he built the legal department and led internal legal activities supporting several transformative pharmaceutical partnerships, a substantial global patent estate, and the companys IPO.
Euphoria Monologue Script, Articles P